肝炎検査ソリューション/診断市場：疾患タイプ、技術、エンドユーザー別-2025-2030年の世界予測

肝炎検査ソリューション/診断市場は、2023年に35億3,000万米ドルと評価され、2024年には37億1,000万米ドルに達すると予測され、CAGR 5.48％で成長し、2030年には51億3,000万米ドルに達すると予測されています。

肝炎検査ソリューションと診断の分野では、さまざまなタイプの肝炎感染（A、B、C、D、E）を検出・管理するために設計されたさまざまな製品と技術が市場範囲に含まれます。これらのソリューションの必要性は、薬物使用の増加、安全でない輸血、無防備な性交渉などの要因による肝炎の発生率の上昇によって大きく後押しされています。その用途は病院、診断研究所、調査機関に及び、エンドユーザーにはヘルスケアプロバイダー、公衆衛生機関、患者個人が含まれます。

同市場は、診断の正確性とスピードを高めるPCR、イムノアッセイ、ポイントオブケア検査の採用など、診断検査における技術的進歩により大幅な成長を遂げています。特に新興市場では、認知度向上とスクリーニングのための政府の取り組みが、成長に大きな影響を与えています。さらに、ヘルスケア支出の増加と早期発見に対する需要の高まりは、市場参入者にとって潜在的な機会を生み出しています。しかし、市場は、高度な検査ソリューションに関連する高コスト、特に新興国市場における限られた認知度、急速な市場浸透を阻害する厳しい規制枠組みなどの制約に直面しています。

技術革新の可能性がある分野としては、低コストで迅速な検査キット、携帯型診断機器の開発、より優れた予測的洞察と患者管理プラットフォームを提供するためのAIベースのデータ分析の改善などが挙げられます。これらの進歩により、資源が限られた環境での幅広いアクセスと実施が大幅に促進される可能性があります。市場の競争は激しく、より堅牢な診断ツールの導入に向けた主要企業間の継続的な進歩や提携が見られます。企業は、差別化された製品を生み出すために、研究開発能力を強化し、技術革新者と戦略的提携を結ぶことに注力すべきです。また、肝炎の予防と検査に関する啓蒙活動を通じて未開拓の市場を開拓することで、市場へのリーチを拡大し、成長を促進することができます。

市場力学：急速に進化する肝炎検査ソリューション/診断市場における主要市場インサイトの解明

肝炎検査ソリューション/診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の肝炎有病率の上昇
  • 疾患の早期発見・診断の必要性
  • 政府や非営利団体による肝炎に対する認識の高まり
• 市場抑制要因
  • 肝炎の検査・診断にかかるコストの高さ
• 市場機会
  • ウイルス性肝炎の検査と診断の進歩
  • ポイントオブケア検査オプションのイントロダクション
• 市場の課題
  • 不正確な検査結果に伴う懸念

ポーターの5つの力：肝炎検査ソリューション/診断市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肝炎検査ソリューション/診断市場における外部からの影響の把握

外部マクロ環境要因は、肝炎検査ソリューション/診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肝炎検査ソリューション/診断市場における競合情勢の把握

肝炎検査ソリューション/診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肝炎検査ソリューション/診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肝炎検査ソリューション/診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肝炎検査ソリューション/診断市場における成功への道筋を描く

肝炎検査ソリューション/診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で肝炎の罹患率が上昇
    • 病気の早期発見と診断の必要性
    • 政府と非営利団体による肝炎に関する意識向上
  • 抑制要因
    • 肝炎の検査と診断にかかる高額な費用
  • 機会
    • ウイルス性肝炎の検査と診断の進歩
    • ポイントオブケア検査オプションのイントロダクション
  • 課題
    • 不正確な検査結果に関連する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肝炎検査ソリューション/診断市場：疾患タイプ別

• A型肝炎
• B型肝炎
• C型肝炎

第7章 肝炎検査ソリューション/診断市場：技術別

• 酵素免疫測定法
• 等温核酸増幅技術
• ポリメラーゼ連鎖反応
• 迅速診断テスト

第8章 肝炎検査ソリューション/診断市場：エンドユーザー別

• 血液銀行
• 診断検査室
• 病院

第9章 南北アメリカの肝炎検査ソリューション/診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の肝炎検査ソリューション/診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの肝炎検査ソリューション/診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • サノフィ、12か月から15歳までの小児のA型肝炎ウイルス感染に対する能動免疫療法として、英国でAVAXIMジュニアの発売を発表
  • ユニットエイドは、薬物注射者や高リスク者のC型肝炎を予防するための危害軽減活動に3,100万米ドルを投資
  • 保健省は地元の研究所と提携し、治癒可能なC型肝炎の検査を拡大
  • ロシュ、二重抗体・抗原C型肝炎ウイルス診断検査を発売
  • アボット、B型肝炎ウイルスを検出するソリューションを発表
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Avantor Inc.
• Beckman Coulter, Inc.
• Bio-Rad Laboratories Inc.
• bioMerieux SA
• Cepheid
• Creative Diagnostics
• DiaSorin S.p.A.
• Epitope Diagnostics, Inc.
• Everlywell, Inc.
• F. Hoffmann-La Roche AG
• FUJIREBIO Inc.
• GenMark Diagnostics, Inc.
• Grifols S.A.
• Hologic, Inc.
• Laboratory Corporation of America Holdings
• MedMira Inc.
• Merck & Co., Inc
• Meridian Bioscience, Inc.
• OraSure Technologies, Inc.
• Ortho Clinical Diagnostics
• Prometheus Laboratories
• QIAGEN GmbH
• Quest Diagnostics Incorporated
• Randox Laboratories
• Sanofi S.A.
• Siemens AG
• Thermo Fisher Scientific Inc.
• Vela Diagnostics
• Werfen, S.A.

LIST OF FIGURES

• FIGURE 1. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET RESEARCH PROCESS
• FIGURE 2. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET DYNAMICS
• TABLE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023

The Hepatitis Test Solution/Diagnosis Market was valued at USD 3.53 billion in 2023, expected to reach USD 3.71 billion in 2024, and is projected to grow at a CAGR of 5.48%, to USD 5.13 billion by 2030.

In the arena of Hepatitis Test Solutions and Diagnostics, the market scope encompasses a range of products and technologies designed to detect and manage different types of hepatitis infections (A, B, C, D, E). The necessity of these solutions is largely propelled by rising incidences of hepatitis due to factors like increased drug use, unsafe blood transfusions, and unprotected sex. Their application spans across hospitals, diagnostic laboratories, and research institutes, with end-users including healthcare providers, public health organizations, and individual patients.

The market is witnessing substantial growth due to technological advancements in diagnostic testing, such as the adoption of PCR, Immunoassays, and point-of-care testing, which enhance the accuracy and speed of diagnosis. Government initiatives to increase awareness and screening, especially in emerging markets, are significantly influencing growth. Additionally, increasing healthcare expenditures and the rising demand for early detection are creating potential opportunities for market players. However, the market faces limitations such as high costs associated with advanced testing solutions, limited awareness, especially in developing regions, and stringent regulatory frameworks that can impede rapid market penetration.

Potential areas of innovation include the development of low-cost, rapid testing kits, portable diagnostic devices, and improvement in AI-based data analytics to provide better predictive insights and patient management platforms. These advances could greatly facilitate wider access and implementation in resource-limited settings. The nature of the market is highly competitive with continuous advancements and collaborations among key players to introduce more robust diagnostic tools. Companies should focus on strengthening their R&D capabilities and forming strategic alliances with technological innovators to create differentiated products. Exploring untapped markets through educational initiatives about hepatitis prevention and testing can also increase market reach and facilitate growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatitis Test Solution/Diagnosis Market

The Hepatitis Test Solution/Diagnosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of hepatitis worldwide
  • Need for earlier detection and diagnosis of diseases
  • Increasing awareness about hepatitis by government and non-profit organizations
• Market Restraints
  • High cost associated with tests and diagnosis of hepatitis
• Market Opportunities
  • Advances in viral hepatitis testing and diagnosis
  • Introduction of point-of-care testing options
• Market Challenges
  • Concerns associated with inaccurate test results

Porter's Five Forces: A Strategic Tool for Navigating the Hepatitis Test Solution/Diagnosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatitis Test Solution/Diagnosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hepatitis Test Solution/Diagnosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatitis Test Solution/Diagnosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hepatitis Test Solution/Diagnosis Market

A detailed market share analysis in the Hepatitis Test Solution/Diagnosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatitis Test Solution/Diagnosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatitis Test Solution/Diagnosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatitis Test Solution/Diagnosis Market

A strategic analysis of the Hepatitis Test Solution/Diagnosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatitis Test Solution/Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Avantor Inc., Beckman Coulter, Inc., Bio-Rad Laboratories Inc., bioMerieux SA, Cepheid, Creative Diagnostics, DiaSorin S.p.A., Epitope Diagnostics, Inc., Everlywell, Inc., F. Hoffmann-La Roche AG, FUJIREBIO Inc., GenMark Diagnostics, Inc., Grifols S.A., Hologic, Inc., Laboratory Corporation of America Holdings, MedMira Inc., Merck & Co., Inc, Meridian Bioscience, Inc., OraSure Technologies, Inc., Ortho Clinical Diagnostics, Prometheus Laboratories, QIAGEN GmbH, Quest Diagnostics Incorporated, Randox Laboratories, Sanofi S.A., Siemens AG, Thermo Fisher Scientific Inc., Vela Diagnostics, and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Hepatitis Test Solution/Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Hepatitis A, Hepatitis B, and Hepatitis C.
• Based on Technology, market is studied across Enzyme-Linked Immunosorbent Assay, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, and Rapid Diagnostic Tests.
• Based on End-User, market is studied across Blood Banks, Diagnostic Laboratories, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of hepatitis worldwide
    • 5.1.1.2. Need for earlier detection and diagnosis of diseases
    • 5.1.1.3. Increasing awareness about hepatitis by government and non-profit organizations
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with tests and diagnosis of hepatitis
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in viral hepatitis testing and diagnosis
    • 5.1.3.2. Introduction of point-of-care testing options
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with inaccurate test results
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hepatitis Test Solution/Diagnosis Market, by Disease Type

• 6.1. Introduction
• 6.2. Hepatitis A
• 6.3. Hepatitis B
• 6.4. Hepatitis C

7. Hepatitis Test Solution/Diagnosis Market, by Technology

• 7.1. Introduction
• 7.2. Enzyme-Linked Immunosorbent Assay
• 7.3. Isothermal Nucleic Acid Amplification Technology
• 7.4. Polymerase Chain Reaction
• 7.5. Rapid Diagnostic Tests

8. Hepatitis Test Solution/Diagnosis Market, by End-User

• 8.1. Introduction
• 8.2. Blood Banks
• 8.3. Diagnostic Laboratories
• 8.4. Hospitals

9. Americas Hepatitis Test Solution/Diagnosis Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Hepatitis Test Solution/Diagnosis Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Hepatitis Test Solution/Diagnosis Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Sanofi Announces Launch of AVAXIM Junior in the UK for Active Immunization Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years
  • 12.3.2. Unitaid Makes USD 31 Million Investment in Harm Reduction Efforts to Prevent Hepatitis C Among People who Inject Drugs and Others at High Risk
  • 12.3.3. DOH Partners with Local Laboratories to Expand Testing for Curable Hepatitis C
  • 12.3.4. Roche Launches Dual Antibody, Antigen Hepatitis C Virus Diagnostic Test
  • 12.3.5. Abbott launches solution to detect Hepatitis B virus
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Avantor Inc.
• 4. Beckman Coulter, Inc.
• 5. Bio-Rad Laboratories Inc.
• 6. bioMerieux SA
• 7. Cepheid
• 8. Creative Diagnostics
• 9. DiaSorin S.p.A.
• 10. Epitope Diagnostics, Inc.
• 11. Everlywell, Inc.
• 12. F. Hoffmann-La Roche AG
• 13. FUJIREBIO Inc.
• 14. GenMark Diagnostics, Inc.
• 15. Grifols S.A.
• 16. Hologic, Inc.
• 17. Laboratory Corporation of America Holdings
• 18. MedMira Inc.
• 19. Merck & Co., Inc
• 20. Meridian Bioscience, Inc.
• 21. OraSure Technologies, Inc.
• 22. Ortho Clinical Diagnostics
• 23. Prometheus Laboratories
• 24. QIAGEN GmbH
• 25. Quest Diagnostics Incorporated
• 26. Randox Laboratories
• 27. Sanofi S.A.
• 28. Siemens AG
• 29. Thermo Fisher Scientific Inc.
• 30. Vela Diagnostics
• 31. Werfen, S.A.